dopaminergic receptor Inhibitors
2 drugsAbout dopaminergic receptor
The dopaminergic receptor family comprises key CNS proteins that bind dopamine, mediating motor control, reward, and cognition.
Dopaminergic receptors are attractive therapeutic targets due to their involvement in key pathways, but currently lack specific genetic evidence linking them to particular diseases.
Two approved drugs, CLOZAPINE and VERSACLOZ, target dopaminergic receptors for CNS disorders; both are small molecules.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Treatment-resistant Schizophrenia with only 1 trials.
Top dopaminergic receptor Drugs
Teva and DOUGLAS PHARMS are the companies with approved drugs targeting dopaminergic receptors.
The market is unconcentrated, suggesting relatively low barriers to entry for new competitors.
dopaminergic receptor Drug Modality Landscape
Modalities
Routes of Administration
dopaminergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing therapies.
dopaminergic receptor Clinical Trials 24 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 3 | 1 | 1 | 1 | 50% |
| Phase 4 | 19 | 11 | 2 | 6 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
dopaminergic receptor Drug Approval Timeline (1996 - 2013)
The first drug was approved in 1996 (CLOZAPINE) and the most recent in 2013 (VERSACLOZ), spanning 18 years.
The approval timeline suggests a potentially saturated market, requiring significant innovation for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting dopaminergic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities